Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Non-cash Items (2023 - 2025)

Historic Non-cash Items for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to $326.8 million.

  • NewAmsterdam Pharma's Non-cash Items rose 407918.57% to $326.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $326.8 million, marking a year-over-year increase of 407918.57%. This contributed to the annual value of $7.9 million for FY2024, which is 5074.0% up from last year.
  • According to the latest figures from Q3 2025, NewAmsterdam Pharma's Non-cash Items is $326.8 million, which was up 407918.57% from $141.1 million recorded in Q2 2025.
  • Over the past 5 years, NewAmsterdam Pharma's Non-cash Items peaked at $326.8 million during Q3 2025, and registered a low of $5.2 million during Q4 2023.
  • For the 3-year period, NewAmsterdam Pharma's Non-cash Items averaged around $85.7 million, with its median value being $7.9 million (2024).
  • As far as peak fluctuations go, NewAmsterdam Pharma's Non-cash Items surged by 5074.0% in 2024, and later surged by 407918.57% in 2025.
  • NewAmsterdam Pharma's Non-cash Items (Quarter) stood at $5.2 million in 2023, then skyrocketed by 50.74% to $7.9 million in 2024, then skyrocketed by 4045.06% to $326.8 million in 2025.
  • Its Non-cash Items stands at $326.8 million for Q3 2025, versus $141.1 million for Q2 2025 and $183.8 million for Q1 2025.